Cited by 342Cancer Immunotherapy and BiomarkersImmune cells in cancerImmunotherapy and Immune Responses

The DOI matches its Crossref record; 184 of the 185 references it cites were found in a registry or an index.

Understanding the tumor microenvironment for effective immunotherapy

Open access

Sadeghi Rad, Habib, Monkman, James, Warkiani, Majid E., Ladwa, Rahul, O'Byrne, Ken, Rezaei, Nima, Kulasinghe, Arutha·2021·Medicinal Research Reviews

DOI 10.1002/med.21765PMC PMC8247330

Open this paper in CoChat — free account Open PDF

Abstract

Advances in immunotherapy have led to durable and long‐term benefits in a subset of patients across a number of solid tumor types. Understanding of the subsets of patients that respond to immune checkpoint inhibitors at the cellular level, and in the context of their tumor microenvironment (TME) is becoming increasingly important. The TME is composed of a heterogeneous milieu of tumor and immune cells. The immune landscape of the TME can inhibit or promote tumor initiation and progression; thus, a deeper understanding of tumor immunity is necessary to develop immunotherapeutic strategies. Recent developments have focused on characterizing the TME immune contexture (type, density, and function) to discover mechanisms and biomarkers that may predict treatment outcomes. This has, in part, been powered by advancements in spatial characterization technologies. In this review article, we address the role of specific immune cells within the TME at various stages of tumor progression and how the immune contexture determinants affecting tumor growth are used therapeutically.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/med.21765

Cites

184 of 184 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400

Flagged first, then by citations

Show all 185 references

1 of the 185 references couldn’t be matched to a known paper.

Sorted by citations

Items 201–300 of 342

The future of interleukin gene therapy in head and neck cancers
Hoch, C. C., Hachani, K., Han, Y., Schmidl, B., Wirth, M., Multhoff, G., Dezfouli, A. B., & Wollenberg, B. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2405568 · Cited by 4
Comprehensive pan-cancer analysis and experiments revealed R3HDM1 as a novel predictive biomarker for prognosis and immune therapy response
Liu, J., Bing, Z., & Wang, J. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1404348 · Cited by 3
Pan-cancer analysis reveals PRRT4 is a potential prognostic factor of AML
Xiang, W., Chen, F., Zhou, H., Ren, G., Qiang, G., & Wang, L. (2025) · Hematology · doi:10.1080/16078454.2025.2496544 · Cited by 2
Pan-cancer analysis of oncogenic role of MAGOH and experiment validation in hepatocellular carcinoma
Qiu, Z., Le, Y., Liao, Y., Chen, X., Xing, X., Nie, F., Wei, X., Wang, H., & Fang, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-08678-9 · Cited by 2
FMRP silencing via siRNA lipid nanoparticles to reprogram the tumor microenvironment and enhance anti-PD-1 efficacy in triple-negative breast cancer
Bai, L., Hao, X., Xu, W., Huang, H., Guo, M., Zhang, Y., Xiang, D.-X., Yang, G., Wu, J., & Chen, C. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102075 · Cited by 2
Recent findings on the PD-1/PD-L1 Axis in breast cancer: Molecular mechanisms, immunotherapeutic potentials, and clinical implications
Ahmadi, R., Sadeghi, K. F., Sharmsar, O., Bagheri, Y., Sadeghi, K. F., Koochehloghmani, H., & Hoseinpourfeyzi, M. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104989 · Cited by 3
Predicability of PD-L1 expression in cancer cells based solely on H&E-stained sections
Faa, G., Fraschini, M., Ziranu, P., Pretta, A., Porcu, G. S., Saba, L., Scartozzi, M., Shokun, N., & Rugge, M. (2025) · Journal of Pathology Informatics · doi:10.1016/j.jpi.2025.100524 · Cited by 3
Genome‐wide CRISPR screen reveals an uncharacterized spliceosome regulator as new candidate immunotherapy target
Shao, T., Liu, C., Kuang, J., Xie, S., Qu, Y., Li, Y., Zhang, L., Liu, F., Qi, Y., Hou, T., et al. (2025) · iMeta · doi:10.1002/imt2.70096 · Cited by 3
Disparities in Tumor Microenvironment Between Primary and Metastatic Colorectal Cancer: Impact on Immune Infiltration and Survival
Dziąg-Dudek, E., Semeniuk-Wojtaś, A., Modzelewska, M., Lubas, A., Róg, L., Górnicka, B., & Stec, R. (2026) · Cancers · doi:10.3390/cancers18040566 · Cited by 2
Establishing human immune system mice: application, opportunity, and challenges
Chiang, P., Lee-Chan, H., & Lee, Y. L. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01777-1 · Cited by 2
Analysis of CMTM6 and CMTM4 expression as potential regulators of the PD-L1 protein and its association with prognosis in glioma cancer
Xue, H. Y., Qiu, B., Wang, H., Jiang, P., Zhang, W., Xue, L., & Wang, J. (2022) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2022108 · Cited by 2
Spatial Transcriptomic Approaches for Understanding the Tumor Microenvironment (TME)
Sadeghirad, H., Shiravand, Y., Radfar, P., Ladwa, R., Warkiani, M. E., O'Byrne, K. J., & Kulasinghe, A. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2022_111 · Cited by 2
Self-citation
Pulmonary Tuberculosis Following Immune Checkpoint Inhibitor Treatment for Recurrent Maxillary Squamous Cell Carcinoma
Kikuta, S., Abe, Y., Shinozaki, K., Seki, N., & Kusukawa, J. (2024) · Cureus · doi:10.7759/cureus.53203 · Cited by 2
Exploratory pilot study to characterize the immune landscapes of malignant pleural effusions and their corresponding primary tumors from patients with breast carcinoma and lung adenocarcinoma
Laberiano-Fernández, C., Gan, Q., Wang, S. M., Tamegnon, A., Wistuba, I. I., Yoon, E. C., Roy‐Chowdhuri, S., & Parra, E. R. (2024) · Journal of the American Society of Cytopathology · doi:10.1016/j.jasc.2024.02.005 · Cited by 2
Enhanced precision in immunotherapy
Bergstrom, E. N., & Alexandrov, L. B. (2024) · Nature Cancer · doi:10.1038/s43018-024-00802-4 · Cited by 3
The Therapeutic Potential of Targeting Tumor Microenvironment and Modulation of Immunotherapy in Gastrointestinal Cancer
Sokhangouy, S. K., Jamialahmadi, H., Sani, M. S. M., Khalili‐Tanha, G., Rouzbahani, A. K., Mahmoudvand, G., Goudarzi, Z., Fakouri, A., Farokhi, S., Hassanian, S. M., et al. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096319027240820055043 · Cited by 2
Elucidating the power of arginine restriction: taming type I interferon response in breast cancer via selective autophagy
Lamsal, A., Andersen, S. B., Johansson, I., Desgarnier, M. D., Wolowczyk, C., Engedal, N., Vietri, M., Bjørkøy, G., Giambelluca, M. S., & Pettersen, K. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01858-6 · Cited by 2
Construction of a lung adenocarcinoma prognostic model based on KEAP1/NRF2/HO‑1 mutation‑mediated upregulated genes and bioinformatic analysis
Zhu, W., Ye, Z., Yang, L., Chen, L., Chen, C., Shi, Q., & Xu, Z. (2025) · Oncology Letters · doi:10.3892/ol.2025.14902 · Cited by 2
Comprehensive Analysis of Multi-Omics Data on RNA Polymerase as an Adverse Factor in Head and Neck Squamous Cell Carcinoma
Gu, Y., Zhang, J., Liu, Y., Zhang, Q., & Geng, Q.-F. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s496748 · Cited by 3
Pan‑cancer analysis of oncogene SFXN1 to identify its prognostic and immunological roles in lung adenocarcinoma
Zhang, L., Wang, S., & Wang, L. (2025) · Oncology Reports · doi:10.3892/or.2025.8883 · Cited by 2
Spatial analysis of malignant-immune cell interactions in the tumor microenvironment using topological data analysis
Park, S. A., Gurnari, D., Dłotko, P., Kim, Y., & Hahn, J. (2026) · npj Systems Biology and Applications · doi:10.1038/s41540-026-00763-7 · Cited by 2
Redox-responsive vesicular carriers for potential tumor-targeting applications
Rathee, S., Sahu, A., Patil, U. K., & Jain, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29125-8.00006-5 · Cited by 2
The Impact of Cancer Therapy on the Cells and Extracellular Vesicles of the Tumor Immune Microenvironment
Bruno, C., Whitcomb, A., Pincock, B., Aleman, I. D., Neves, J. H., Shaw, M., & Gonda, A. (2025) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-25-0101 · Cited by 2
Spatial profiling technologies for research and clinical application in head and neck squamous cell cancers
Nieszporek, A., Wierzbicka, M., Khan, A., Jeziorny, M., Kraiński, P., Cybińska, J., & Gazińska, P. (2025) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2025.100321 · Cited by 3
Identification of molecular patterns and prognostic models of epithelial–mesenchymal transition- and immune-combined index in the gastric cancer
Zhang, X., Li, Y., Hu, P., Xu, L., & Qiu, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.958070 · Cited by 2
Immune Checkpoint Inhibitors - New Insights and Recent Progress
Raza, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100958 · Cited by 2
Construction of immune cell infiltration score model to assess prognostic ability of tumor immune environment in lung adenocarcinoma.
Tian, J., Fu, C., Peng, Q., Yang, J., Fan, X., Zeng, X., Qing, W., & Wu, Y. (2023) · PubMed Central · Cited by 2
Modulating the dynamics of NFκB and PI3K enhances the ensemble-level TNFR1 signaling mediated apoptotic response
Sherekar, S., Todankar, C. S., & Viswanathan, G. A. (2023) · npj Systems Biology and Applications · doi:10.1038/s41540-023-00318-0 · Cited by 2
Frozen tissue coring and layered histological analysis improves cell type-specific proteogenomic characterization of pancreatic adenocarcinoma
Savage, S. R., Wang, Y., Chen, L., Jewell, S. D., Newton, C. J., Dou, Y., Li, Q. K., Bathe, O. F., Robles, A. I., Omenn, G. S., et al. (2024) · Clinical Proteomics · doi:10.1186/s12014-024-09450-3 · Cited by 2
Evaluating the Efficacy, Durability, and Clinical Implications of Zirconia vs. Titanium Dental Implants: A Comprehensive ReviewPreprint
Jaber, M. A., Jaber, A. M., El-Ameen, A. M., & Elameen, F. M. (2024) · Preprints.org · doi:10.20944/preprints202408.0331.v1 · Cited by 2
Bioinformatics analysis and identification of cuproptosis-related long non-coding RNAs in colorectal cancer
Chen, W., Huang, D., Su, X., Su, Y., & Li, S. (2024) · Journal of International Medical Research · doi:10.1177/03000605241274563 · Cited by 1
RETRACTED: The cellular signaling and regulatory role of protein phosphatase in tumor diagnosis: Upstream miRNAs of PTEN
He, Y., Mingyan, E., Liu, S., Liu, G., & Yang, C. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136179 · Cited by 1
Retracted
Notch3 and Its Clinical Importance in Ovarian Cancer
Jit, B. P., Behera, A., Qazi, S., Mittal, K., Kundu, S., Bansal, B., Ray, M. D., & Sharma, A. K. (2024) · Drugs and Drug Candidates · doi:10.3390/ddc3040040 · Cited by 1
Gut microbiome and tumor immunotherapy
Vig, M., & Dubey, S. (2025) · International review of cytology · doi:10.1016/bs.ircmb.2024.12.014 · Cited by 1
Comprehensive systems biology analysis reveals splicing factor contributions to cutaneous melanoma progression
Zhu, S., Zhu, R., Wang, Y., Zhu, J., Zong, Y., Zhu, L., & Guo, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-93695-x · Cited by 1
Futuro de la oncología personalizada y el diagnóstico molecular
Ruíz-Patiño, A. (2024) · Medicina · doi:10.56050/01205498.2375 · Cited by 1
Statins as potential adjuvant therapy in lung cancer: a narrative review
Tian, Y., Li, J., & Yang, X. (2025) · Journal of Thoracic Disease · doi:10.21037/jtd-2025-66 · Cited by 1
Chromatin Preparation from Frozen Tissues for Chromatin Immunoprecipitation (ChIP) Assays
López, V., & Fraga, M. F. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4558-1_14 · Cited by 1
Prognostic value of serum albumin-creatinine ratio as a biomarker in patients treated with immune checkpoint inhibitors
Baş, O., Tokatlı, M., Güdük, N., Erdoğan, D., Boyraz, N. E., Kavgacı, G., Şahin, T. K., Güven, D. C., Kertmen, N., Aksoy, S., et al. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2513850 · Cited by 1
Nanoparticle-based methionine and AICAR delivery elicits a robust antitumor immune response
Gu, Y., Nguyễn, B. L., Mishra, S. K., Pokhrel, R. H., Sharma, M., Pandit, M., Pham, L. M., Patil, B. R., Kim, J., Kim, J. O., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113981 · Cited by 1
Comprehensive analysis of the PLXNA3 gene on prognosis and immune characteristics in breast cancer
Sun, W. H., Xu, Y., Qi, Q., Zhang, W., Pan, H., Sun, G., Wang, S., & Zhou, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-13843-1 · Cited by 1
Toward real clinical utility: leveraging comprehensive cancer proteomic datasets for clinical insight
Rodland, K., & Zhang, B. (2025) · Expert Review of Proteomics · doi:10.1080/14789450.2025.2580647 · Cited by 2
Comprehensive analysis of palmitoylation-related proteins for prognostic risk evaluation and tumor immune microenvironment assessment in glioma
Xue, J., Lin, L., Liu, C., Yin, Q., Wang, T., Lai, R., Chen, L., Yin, Y., Wang, M., & Zhou, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1599769 · Cited by 1
The prognostic significance of JAML and its role in remodeling the immune microenvironment via the cGAS-STING pathway in endometrial cancer
Tian, C., 姚远洋, Tu, Y., Yu, J., Gong, C., Shi, X., Yu, H., & Jiang, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1738596 · Cited by 1
Smoking Behavior Is Associated With an Altered Immune Landscape in Prostate Cancer: Implications for Patient Outcomes
Sharma, A., Sudan, S. K., Khan, M. A., Tahir, M., Niyogi, P. G., Singh, A. P., & Singh, S. (2026) · The Prostate · doi:10.1002/pros.70142 · Cited by 1
Interaction of HIF-1a with various cell death pathways in tumor immune microenvironment (TIME)
Varkiani, M. M., Faghihkhorasani, F., Moosavi, M., Habibi, R., Mirzaei, H., Karimi, N., Etemad, S., Karami, P., Osati, P., Aref, A. R., et al. (2026) · APOPTOSIS · doi:10.1007/s10495-025-02249-z · Cited by 6
Bioprinted Tumor Microenvironment Models Reveal Immune Evasion and Guide CAR‐NK Therapeutic Strategies
Kim, D., Jo, S., Jang, I.-H., Kim, Y., Jung, Y., Ahn, J., Lim, H., Lee, J. J., Lee, K., Kim, T., et al. (2026) · Advanced Science · doi:10.1002/advs.202521188 · Cited by 1
Combined immune and DDR pathway classifier: A novel pathway-based classification aimed at tailoring personalized therapies for acute myeloid leukemia patients
Huang, Y., Zhang, Y., Zhou, Q., Teng, Y., Sui, M., & Zhang, F. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107093 · Cited by 1
The potential use and experimental validation of genomic instability-related lncRNA in pancreatic carcinoma
Xia, X., Zhao, S., Song, X., Zhang, M., Zhu, X., Li, C., Chen, W., & Zhao, D. (2023) · Medicine · doi:10.1097/md.0000000000035300 · Cited by 1
Noncoding RNA-Mediated High Expression of PFKFB3 Correlates with Poor Prognosis and Tumor Immune Infiltration of Lung Adenocarcinoma
Gu, X., Li, X., Zhang, X., Li, T., Feng, R., Liu, L., Sun, H., Zhang, Q., Bian, T., Zhang, J., et al. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s416155 · Cited by 1
Pembrolizumab-Induced Colitis and Diarrhea in the Treatment of Sporadic Colorectal Cancer: A Case Report
Jose, R., Kaur, J., Blanco, T., Ehrlich, S., & Marcelin, M. (2024) · Cureus · doi:10.7759/cureus.52636 · Cited by 1
State-of-the-Art Cancer Immunotherapies
Nagase, H., Kato, T., & Yoshimoto, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052532 · Cited by 1
Prognostic Significance of CD11b-, CD8-, and CD163-Positive Tumor-Infiltrating Immune Cells in Distal Bile Duct Cancer
Choi, J. H., Kim, J. Y., Lee, K. R., Lee, G. Y., Hong, M. E., Hwang, H. W., Lee, M. Y., Kim, M. K., & Hong, S. A. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14101033 · Cited by 1
Boosting antitumor immunity in breast cancers: Potential of adjuvants, drugs, and nanocarriers
Chen, P., Ren, L., Guo, Y.-W., & Sun, Y. (2024) · International Reviews of Immunology · doi:10.1080/08830185.2024.2432499 · Cited by 2
Comprehensive Pan-Cancer Analysis and Functional Studies Reveal SLC2A6 as a Ferroptosis Modulator in Hepatocellular carcinoma
Yan, G., Huang, H., Lu, Z., Chen, M., Wang, X., Zhong, P., Qin, C., Mo, S., Han, C., Luo, X., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-85504-2 · Cited by 1
Nanoparticle-Mediated Delivery of RNA-Based Therapeutics for Colon Cancer: Current Status and Future Prospects
Sharma, M., Dande, P. R., Saraf, A., Gawad, J., Maheshwari, R., & Ashique, S. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815305906125010015 · Cited by 1
Upregulated PXDNL promotes invasive breast carcinoma progression
Zhou, X. (2025) · American Journal of Translational Research · doi:10.62347/bouc4040 · Cited by 1
Comprehensive analysis of anosmin-1 as a potential biomarker and its correlation with epithelial–mesenchymal transition in advanced gastric cancer
Zhou, X., Pan, Y., Li, H., Sun, Y., Li, Y., Jiang, Y.-X., & Liu, T. (2025) · 3 Biotech · doi:10.1007/s13205-025-04361-y · Cited by 1
Identification of Anoikis‐Related Subgroups and Prognosis Model in Colon Cancer
Shaokang, Y., Yang, P., Liu, Z., Chen, Y., He, Q., & Wang, D. (2025) · Cancer Nexus · doi:10.1002/cnx2.70008 · Cited by 1
Nivolumab-Induced Refractory Hemorrhagic Gastritis and Duodenitis Requiring Multimodal Biologic Therapy
Shibu, R., Scully, K., Mohsen, W., Mason, R., & Pillai, S. R. (2025) · ACG Case Reports Journal · doi:10.14309/crj.0000000000001782 · Cited by 1
Current Advances in Immune Checkpoint Therapy
Russell, B. L., Malindisa, S. T., Sooklal, S. A., & Ntwasa, M. M. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.107315 · Cited by 1
Oncolytic adenovirus H101 enhanced antitumor effects of PD-1 blockade by downregulating CD47 on tumor cellsPreprint
Qiao, C., Wang, S., Xu, Y., He, Y., Cai, Z., & Wang, H. (2023) · Research Square · doi:10.21203/rs.3.rs-2823970/v1 · Cited by 1
Author Index
Authors, V. (2013) · Current Oncology · doi:10.3747/co.20.1906
Polymeric micelles as delivery systems for anticancer immunotherapy
Parayath, N. N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89868-3.00004-5
Mining of clinical and prognosis related genes in the tumor microenvironment of endometrial cancerPreprint
Li, W., Qin, Y., Chen, X., & Wang, X. (2022) · Research Square · doi:10.21203/rs.3.rs-2151236/v1
The Potential Success and Setbacks of CAR-T Cell Therapy
Wang, A. H. (2022) · American Journal of Biomedical Science & Research · doi:10.34297/ajbsr.2022.17.002309
Identification and validation of obesity related genes signature based on microenvironment phenotypes in prostate adenocarcinomPreprint
Liang, L., Shang, J., Zhang, Y., Xu, Y., Zhouteng, Y., Wen, J., Zhao, Y., Feng, N., & Zhao, R. (2023) · Research Square · doi:10.21203/rs.3.rs-2649940/v1
Role of Cancer-Associated Adipocytes in the Progression of Breast Cancer
Jurj, A. M., Ciocan, C. A., Ráduly, L., Zănoagă, O., Berindan‐Neagoe, I., & Braicu, C. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_54-1
Recent advancements in tumour microenvironment landscaping for target selection and response prediction in immune checkpoint therapies achieved through spatial protein multiplexing analysis
Andhari, M. D., Antoranz, A., Smet, F. D., & Bosisio, F. M. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.05.009 · Cited by 1
Mining of clinical and prognosis related genes in the tumor microenvironment of endometrial cancer: A field synopsis of observational study
Li, W., Qin, Y., Chen, X., & Wang, X. (2023) · Medicine · doi:10.1097/md.0000000000034047
CAR T cells and dendritic cells: vaccinomics perspectives
Anurogo, D. (2023) · International Physical Medicine & Rehabilitation Journal · doi:10.15406/ipmrj.2023.08.00347
[Exploring the Role of DKK1 in the Occurrence of Lung Adenocarcinoma Based on the Analysis of Bioinformatics].
Lu, R., Li, Y., Abuduhailili, X., Yu, T., & Feng, Y. (2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.101.22
Identification and validation of obesity related genes signature based on microenvironment phenotypes in prostate adenocarcinoma
Liang, L., Shang, J., Zhang, Y., Xu, Y., Zhouteng, Y., Wen, J., Zhao, Y., Feng, N., & Zhao, R. (2023) · Aging · doi:10.18632/aging.205065
A comprehensive prognostic and immune analysis of SFXN1 in Pan-cancerPreprint
Zhang, L., Li, W., Wang, S., & Wang, L. (2023) · Research Square · doi:10.21203/rs.3.rs-3652487/v1
A pan-cancer analysis has uncovered CCDC58, a mitochondrial gene associated with epilepsy, as a potential prognostic and immunotherapeutic biomarker for various cancer types, including gliomasPreprint
You, Z., Huang, C., Li, J., Liu, Y., Fan, W., Fan, Z., Liu, X., & Sun, J. (2024) · Research Square · doi:10.21203/rs.3.rs-3896655/v1
Association between serum albumin-creatinine ratio and survival in patients treated with immune checkpoint inhibitorsPreprint
Baş, O., Tokatlı, M., Güdük, N., Erdoğan, D., Boyraz, N. E., Kavgacı, G., Şahin, T. K., Güven, D. C., Kertmen, N., Aksoy, S., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4094445/v1
Cancer nanoimmunotherapy in the present scenario
Ancira-Cortez, A., Gibbens-Bandala, B., Cruz-Nova, P., Meléndez‐Alafort, L., & Ocampo‐García, B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15518-5.00021-5
Additional file 1 of Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer
Liu, L., Mo, M., Chen, X., Chao, D., Zhang, Y., Chen, X., Wang, Y., Zhang, N., He, N., Yuan, X., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22631484
Additional file 1 of Polyamine metabolism patterns characterized tumor microenvironment, prognosis, and response to immunotherapy in colorectal cancer
Zhang, E., Ding, C., Li, S., Aikemu, B., Zhou, X., Fan, X., Sun, J. P., Yang, X., & Zheng, M. (2023) · Figshare · doi:10.6084/m9.figshare.22949328
Additional file 2 of Polyamine metabolism patterns characterized tumor microenvironment, prognosis, and response to immunotherapy in colorectal cancer
Zhang, E., Ding, C., Li, S., Aikemu, B., Zhou, X., Fan, X., Sun, J., Yang, X., & Zheng, M. (2023) · Figshare · doi:10.6084/m9.figshare.22949331
Integrated single-cell and bulk RNA-seq for constructing a prognostic risk model of immune-related genes in colorectal cancerPreprint
Xiong, Y., Xiong, W., Wang, Y., He, C. H., Zhan, Y., Pan, L., Luo, L., & Song, R. (2024) · Research Square · doi:10.21203/rs.3.rs-4173067/v1
mRNA-based cancer therapeutics
Hillery, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28934-7.00006-6
A Comprehensive Analysis of the Cuproptosis-Related Gene GCSH in Pan-Cancer with a Focus on Colorectal CancerPreprint
Guo, X., Lei, R., Li, J., Shen, L., & Ding, Z. (2024) · Research Square · doi:10.21203/rs.3.rs-5382756/v1
Host directed immunotherapy for chronic infections and cancer
Tiwari, R., Singh, V. K., Gautam, V., Mehrotra, S., & Kumar, R. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2024.10.009
Overcoming immunotherapeutic drug resistance in pancreatic and colon cancers
Tavakoli, M., Raza, H., Ukwade, D., Nwachukwu, D., Mohamed, S., & Ali, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24742-2.00028-9
Single-cell analysis of colon cancer: Novel insight into drug resistance and immunotherapy
Bhamidipati, P., Kocharlakota, S. V., Katneni, V., & Malla, R. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24742-2.00010-1
Human Microbiota and Metabolic Alteration in Cancer Progression and Treatment
Shakartalla, S. B., Elsayed, T. M., Almsailem, F., Almousa, F., Aldaihani, A., & Soliman, S. S. M. (2025) · Springer eBooks · doi:10.1007/978-981-96-1305-2_16
C9orf50 is a Targetable Spliceosome Regulator for Cancer ImmunotherapyPreprint
Shao, T., Liu, C., Kuang, J., Xie, S., Qu, Y., Li, Y., Liu, F., Zhang, L., Li, M. X., Hou, T., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.13.642772
A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours
Price, T. J., Ługowska, I., Chawla, S. P., Falchook, G. S., Subbiah, V., Monzon, J. G., Arkenau, H., Hui, M. N., Kuboki, Y., Dziadziuszko, R., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-088578
Comprehensive analysis of phagocytosis regulatory genes in bladder cancer: implications for prognosis and immunotherapy
Ma, X., Yao, D., Yu, W., Wu, G., Fan, C.-W., & Tian, J. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1608519
Sonographic Signatures of Immune Checkpoint Inhibitor-Associated Musculoskeletal Adverse Events
von Eckstaedt, H. V., Weng, K., Sacksen, I., Stovall, R., Grivas, P. D., Bhatia, S., Hall, E. T., Pollock, S., & Singh, N. (2025) · Cancers · doi:10.3390/cancers17142344
Prognostic and immunological significance of CD82 in cancers with focus on hepatocellular carcinoma: A bioinformatics approach
Ali, S., Liu, S., Chen, J., Ullah, J., Mou, G., & Huang, X. (2025) · Medicine · doi:10.1097/md.0000000000043396
Comprehensive analysis of VDAC1 in gynecological tumors and structure-based virtual screening of its natural inhibitors
Li, H., Jin, Y., Huang, Q. B., Xie, X., & Li, N. (2025) · Medical Oncology · doi:10.1007/s12032-025-03048-x
Cardiac Dysfunction and Heart Failure Caused by Cancer Therapy-Induced Cardiotoxicity
Șoșdean, R., Giuchici, S., Ionică, L. N., Furdui-Lința, A. V., Sturza, A., Muntean, D. M., Lighezan, D., & Bolli, R. (2025) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-90598-8_2
Beyond Tumor Suppression: The Multifaceted Functions of HOPX in Tissue Differentiation, Metabolism, and Immunity
Munzert, F., Nenkov, M., Berndt, A., Sandhaus, T., Lang, S. M., Gaßler, N., & Chen, Y. (2025) · Cells · doi:10.3390/cells14211718
Personalized approach to systemic treatment of bladder cancer: molecular and genetic markers and new therapeutic strategies (literature review)
Lyubchenko, L. N., Ghazaryan, K. A., Chernavina, K. M., Zaborskii, I. N., Karyakin, O. B., & Каприн, А. Д. (2025) · Cancer Urology · doi:10.17650/1726-9776-2025-21-3-170-189
Additional file 5 of Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy response
Sadeghirad, H., Monkman, J. H., Tan, C. W., Liu, N., Yunis, J., Donovan, M. L., Moradi, A., Jhaveri, N., Perry, C., Adams, M. N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26753260
Self-citation
Additional file 1 of Crosstalk between metabolism and cell death in tumorigenesis
Yang, S., Hu, C., Chen, X., Tang, Y., Li, J., Yang, H., Yang, Y., Ying, B., Xiao, X., Li, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26702152
Additional file 3 of Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy response
Sadeghirad, H., Monkman, J. H., Tan, C. W., Liu, N., Yunis, J., Donovan, M. L., Moradi, A., Jhaveri, N., Perry, C., Adams, M. N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26753254
Self-citation
Additional file 2 of Frozen tissue coring and layered histological analysis improves cell type-specific proteogenomic characterization of pancreatic adenocarcinoma
Savage, S. R., Wang, Y., Chen, L., Jewell, S. D., Newton, C. J., Dou, Y., Li, Q. K., Bathe, O. F., Robles, A. I., Omenn, G. S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26674523

Authors: Sadeghi Rad, H., Monkman, J., Warkiani, M. E., Ladwa, R., O'Byrne, K., Rezaei, N., & Kulasinghe, A.
Affiliations: School of Medicine Tehran University of Medical Sciences Tehran Iran
Translational Research Institute (AU)
University of Technology Sydney (AU)
Princess Alexandra Hospital (AU)
The School of Biomedical Sciences, Institute of Health and Biomedical Innovation Queensland University of Technology Brisbane Queensland Australia
Universal Scientific Education and Research Network (IR)
Corresponding author: Rezaei, Nima
Kulasinghe, Arutha
ORCID: Monkman, James
Warkiani, Majid E.
Ladwa, Rahul
O'Byrne, Ken
Rezaei, Nima
Kulasinghe, Arutha
Venue: Medicinal Research Reviews
Publisher: Wiley
Published: 2020-12-04
Volume: 41
Issue: 3
Pages: 1474-1498
ISSN: 0198-6325 (ISSN-L)
1098-1128
DOI: 10.1002/med.21765
PMC: PMC8247330
OpenAlex: W3108853735
Cited by: 334
References: 185
Citations by year: 2026: 46 · 2025: 79 · 2024: 99 · 2023: 49 · 2022: 50 · 2021: 9 · 2020: 1
FWCI: 2.99
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc
creativecommons.org/licenses/by-nc/4.0/ (vor)
Locations: Medicinal Research Reviews (publishedVersion, cc-by-nc)
PubMed Central (publishedVersion, cc-by-nc)
PubMed (publishedVersion)
QUT ePrints (Queensland University of Technology) (submittedVersion, cc-by-nc)
Funders: Garnett Passe and Rodney Williams Memorial Foundation
National Health and Medical Research Council (1157741)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: tumor microenvironment, cancer immunotherapy, immune checkpoint inhibitors, immune contexture, tumor-infiltrating immune cells, predictive biomarkers, treatment response, tumor progression, antitumor immunity
MeSH terms: Humans, Immunotherapy, Neoplasms, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Understanding the tumor microenvironment for effective immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks